Current progress in ABO-incompatible liver transplantation

Minoru Tanabe, Shigeyuki Kawachi, Hideaki Obara, Masahiro Shinoda, Taizo Hibi, Yuukou Kitagawa, Go Wakabayashi, Motohide Shimazu, Masaki Kitajima

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background ABO-incompatible (ABOi) living donor liver transplantation (LDLT) in adult patients has been controversial because of the high risk of antibody-mediated rejection (AMR) mediated by preformed anti-ABO antibodies. However, outcomes have recently improved owing to various treatment advances. Materials and methods This review article describes the history and current progress in ABOi liver transplantation, mainly from the viewpoint of the Japanese experience. Results The typical clinical manifestations of AMR are hepatic necrosis and intrahepatic biliary complication. The outcomes of early ABOi LDLT were poor, especially in older children and adult cases. Since we first introduced portal vein infusion therapy into adult ABOi LDLT in 1998, local graft infusion therapy has emerged in Japan as a crucial breakthrough to overcome the ABO blood group barrier. From 2003, rituximab prophylaxis has been widely used with local graft infusion, and has resulted in markedly improved patient survival. The novel approach of intravenous immunoglobulin induction may become another option to suppress AMR. Continued patient enrolment and controlled trials will allow further validation of these treatments. Conclusions The outcome of ABOi LDLT is now similar to that of blood-type-matched transplantation in Japan. However, infection is the major cause of morbidity and mortality after ABOi LDLT. Thus, evaluation of the patients' immune status and adjustment of immunosuppression will be the way forward in the future.

Original languageEnglish
Pages (from-to)943-949
Number of pages7
JournalEuropean Journal of Clinical Investigation
Volume40
Issue number10
DOIs
Publication statusPublished - 2010 Oct

Fingerprint

Living Donors
Liver
Liver Transplantation
Antibodies
Grafts
Japan
Transplants
Intravenous Immunoglobulins
Therapeutics
Blood Group Antigens
Portal Vein
Immunosuppression
Anti-Idiotypic Antibodies
Blood
Necrosis
Transplantation
History
Morbidity
Survival
Mortality

Keywords

  • ABO-incompatible
  • antibody-mediated rejection
  • liver transplantation
  • living donor
  • rituximab

ASJC Scopus subject areas

  • Medicine(all)
  • Clinical Biochemistry
  • Biochemistry

Cite this

Current progress in ABO-incompatible liver transplantation. / Tanabe, Minoru; Kawachi, Shigeyuki; Obara, Hideaki; Shinoda, Masahiro; Hibi, Taizo; Kitagawa, Yuukou; Wakabayashi, Go; Shimazu, Motohide; Kitajima, Masaki.

In: European Journal of Clinical Investigation, Vol. 40, No. 10, 10.2010, p. 943-949.

Research output: Contribution to journalArticle

Tanabe, Minoru ; Kawachi, Shigeyuki ; Obara, Hideaki ; Shinoda, Masahiro ; Hibi, Taizo ; Kitagawa, Yuukou ; Wakabayashi, Go ; Shimazu, Motohide ; Kitajima, Masaki. / Current progress in ABO-incompatible liver transplantation. In: European Journal of Clinical Investigation. 2010 ; Vol. 40, No. 10. pp. 943-949.
@article{d18d4f6c8e744f96aadaa6ec85180801,
title = "Current progress in ABO-incompatible liver transplantation",
abstract = "Background ABO-incompatible (ABOi) living donor liver transplantation (LDLT) in adult patients has been controversial because of the high risk of antibody-mediated rejection (AMR) mediated by preformed anti-ABO antibodies. However, outcomes have recently improved owing to various treatment advances. Materials and methods This review article describes the history and current progress in ABOi liver transplantation, mainly from the viewpoint of the Japanese experience. Results The typical clinical manifestations of AMR are hepatic necrosis and intrahepatic biliary complication. The outcomes of early ABOi LDLT were poor, especially in older children and adult cases. Since we first introduced portal vein infusion therapy into adult ABOi LDLT in 1998, local graft infusion therapy has emerged in Japan as a crucial breakthrough to overcome the ABO blood group barrier. From 2003, rituximab prophylaxis has been widely used with local graft infusion, and has resulted in markedly improved patient survival. The novel approach of intravenous immunoglobulin induction may become another option to suppress AMR. Continued patient enrolment and controlled trials will allow further validation of these treatments. Conclusions The outcome of ABOi LDLT is now similar to that of blood-type-matched transplantation in Japan. However, infection is the major cause of morbidity and mortality after ABOi LDLT. Thus, evaluation of the patients' immune status and adjustment of immunosuppression will be the way forward in the future.",
keywords = "ABO-incompatible, antibody-mediated rejection, liver transplantation, living donor, rituximab",
author = "Minoru Tanabe and Shigeyuki Kawachi and Hideaki Obara and Masahiro Shinoda and Taizo Hibi and Yuukou Kitagawa and Go Wakabayashi and Motohide Shimazu and Masaki Kitajima",
year = "2010",
month = "10",
doi = "10.1111/j.1365-2362.2010.02339.x",
language = "English",
volume = "40",
pages = "943--949",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Current progress in ABO-incompatible liver transplantation

AU - Tanabe, Minoru

AU - Kawachi, Shigeyuki

AU - Obara, Hideaki

AU - Shinoda, Masahiro

AU - Hibi, Taizo

AU - Kitagawa, Yuukou

AU - Wakabayashi, Go

AU - Shimazu, Motohide

AU - Kitajima, Masaki

PY - 2010/10

Y1 - 2010/10

N2 - Background ABO-incompatible (ABOi) living donor liver transplantation (LDLT) in adult patients has been controversial because of the high risk of antibody-mediated rejection (AMR) mediated by preformed anti-ABO antibodies. However, outcomes have recently improved owing to various treatment advances. Materials and methods This review article describes the history and current progress in ABOi liver transplantation, mainly from the viewpoint of the Japanese experience. Results The typical clinical manifestations of AMR are hepatic necrosis and intrahepatic biliary complication. The outcomes of early ABOi LDLT were poor, especially in older children and adult cases. Since we first introduced portal vein infusion therapy into adult ABOi LDLT in 1998, local graft infusion therapy has emerged in Japan as a crucial breakthrough to overcome the ABO blood group barrier. From 2003, rituximab prophylaxis has been widely used with local graft infusion, and has resulted in markedly improved patient survival. The novel approach of intravenous immunoglobulin induction may become another option to suppress AMR. Continued patient enrolment and controlled trials will allow further validation of these treatments. Conclusions The outcome of ABOi LDLT is now similar to that of blood-type-matched transplantation in Japan. However, infection is the major cause of morbidity and mortality after ABOi LDLT. Thus, evaluation of the patients' immune status and adjustment of immunosuppression will be the way forward in the future.

AB - Background ABO-incompatible (ABOi) living donor liver transplantation (LDLT) in adult patients has been controversial because of the high risk of antibody-mediated rejection (AMR) mediated by preformed anti-ABO antibodies. However, outcomes have recently improved owing to various treatment advances. Materials and methods This review article describes the history and current progress in ABOi liver transplantation, mainly from the viewpoint of the Japanese experience. Results The typical clinical manifestations of AMR are hepatic necrosis and intrahepatic biliary complication. The outcomes of early ABOi LDLT were poor, especially in older children and adult cases. Since we first introduced portal vein infusion therapy into adult ABOi LDLT in 1998, local graft infusion therapy has emerged in Japan as a crucial breakthrough to overcome the ABO blood group barrier. From 2003, rituximab prophylaxis has been widely used with local graft infusion, and has resulted in markedly improved patient survival. The novel approach of intravenous immunoglobulin induction may become another option to suppress AMR. Continued patient enrolment and controlled trials will allow further validation of these treatments. Conclusions The outcome of ABOi LDLT is now similar to that of blood-type-matched transplantation in Japan. However, infection is the major cause of morbidity and mortality after ABOi LDLT. Thus, evaluation of the patients' immune status and adjustment of immunosuppression will be the way forward in the future.

KW - ABO-incompatible

KW - antibody-mediated rejection

KW - liver transplantation

KW - living donor

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=77956554854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956554854&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2362.2010.02339.x

DO - 10.1111/j.1365-2362.2010.02339.x

M3 - Article

C2 - 20636381

AN - SCOPUS:77956554854

VL - 40

SP - 943

EP - 949

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 10

ER -